The main focus of the “Metabolic control of cell deaths” lab is to understand how the deregulated metabolism of cancer cells might impact their response to chemotherapy and to the anti-cancer immune response. The laboratory mainly focuses on the study of non-Hodgkin B lymphomas. Lymphoma is a common cancer in the Western world. 90% of aggressive lymphomas originate from B-cells and are classified as diffuse large B-cell lymphomas (DLBCLs), a genetically heterogeneous group of tumors. Their main two work lines are: (i) to determine if the inhibition of the metabolism can modulate cell death and the anti-cancer immune response, and (ii) analyze the role of non-metabolic functions of glycolytic enzymes in oncogenesis and response to treatment.
INSERM U1065, C3M
Bâtiment Universitaire ARCHIMED
151 route Saint Antoine de Ginestière
BP 2 3194 (respecter l'espace après le 2)
06204 NICE CEDEX 3, France
T +33 (0)489064304
Contact e-mail
Visit website
As part of our MSCA-ESR training on complementary skills we got to leave the wet lab to explore what happens on the other side of the bench and to learn what it means to be a scientific editor. This is our story.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
